Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.

Lee HJ Jr, Macomber MW, Spraker MB, Bowen SR, Hippe DS, Fung A, Russell KJ, Laramore GE, Rengan R, Liao J, Apisarnthanarax S, Zeng J.

Radiat Oncol. 2018 Sep 17;13(1):179. doi: 10.1186/s13014-018-1127-6.

PMID:
30223877
2.

Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging.

Lee HJ Jr, Zeng J, Vesselle HJ, Patel SA, Rengan R, Bowen SR.

Int J Radiat Oncol Biol Phys. 2018 Jun 1. pii: S0360-3016(18)30903-9. doi: 10.1016/j.ijrobp.2018.05.051. [Epub ahead of print]

PMID:
30108002
3.

The Practicality of ICRU and Considerations for Future ICRU Definitions.

Shepherd A, James SS, Rengan R.

Semin Radiat Oncol. 2018 Jun;28(3):201-206. doi: 10.1016/j.semradonc.2018.02.005. Review.

PMID:
29933880
4.

Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer.

Lee HJ Jr, Zeng J, Rengan R.

Transl Lung Cancer Res. 2018 Apr;7(2):180-188. doi: 10.21037/tlcr.2018.03.28. Review.

5.

Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer.

Smith WP, Richard PJ, Zeng J, Apisarnthanarax S, Rengan R, Phillips MH.

Transl Lung Cancer Res. 2018 Apr;7(2):122-133. doi: 10.21037/tlcr.2018.03.27.

6.

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer.

Maes D, Saini J, Zeng J, Rengan R, Wong T, Bowen SR.

Transl Lung Cancer Res. 2018 Apr;7(2):114-121. doi: 10.21037/tlcr.2018.04.04.

7.

Proton therapy in non-small cell lung cancer.

Rengan R, Zeng J.

Transl Lung Cancer Res. 2018 Apr;7(2):103-105. doi: 10.21037/tlcr.2018.04.13. No abstract available.

8.

Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer.

Rengan R, Redman M, Zeng J.

J Clin Oncol. 2018 Jul 1;36(19):2003-2004. doi: 10.1200/JCO.2018.78.3803. Epub 2018 May 10. No abstract available.

PMID:
29746228
9.

4D computed tomography scans for conformal thoracic treatment planning: is a single scan sufficient to capture thoracic tumor motion?

Tseng YD, Wootton L, Nyflot M, Apisarnthanarax S, Rengan R, Bloch C, Sandison G, St James S.

Phys Med Biol. 2018 Jan 18;63(2):02NT03. doi: 10.1088/1361-6560/aaa44e.

PMID:
29346116
10.
11.

The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer.

Kesarwala AH, Lu DJ, Xanthopoulos E, Apisarnthanarax S, Cengel KA, Evans TL, Aggarwal C, Cohen RB, Langer CJ, Rengan R, Simone CB 2nd.

Clin Lung Cancer. 2018 Mar;19(2):e205-e209. doi: 10.1016/j.cllc.2017.10.001. Epub 2017 Oct 12.

PMID:
29153967
12.

The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients.

McNew LK, Bowen SR, Gopan O, Nyflot MJ, Patel SA, Zeng J, Rengan R.

Adv Radiat Oncol. 2017 Feb 1;2(2):192-196. doi: 10.1016/j.adro.2017.01.008. eCollection 2017 Apr-Jun.

13.

Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.

Rwigema JM, Verma V, Lin L, Berman AT, Levin WP, Evans TL, Aggarwal C, Rengan R, Langer C, Cohen RB, Simone CB 2nd.

Cancer. 2017 Nov 1;123(21):4244-4251. doi: 10.1002/cncr.30870. Epub 2017 Jul 5.

PMID:
28678434
14.

Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer: The Right Dose, in the Right Location, to the Right Patient, at the Right Time.

Zeng J, Rengan R.

JAMA Oncol. 2017 Oct 1;3(10):1365-1367. doi: 10.1001/jamaoncol.2017.1344. No abstract available.

PMID:
28570727
15.

Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma.

Kalbasi A, Rengan R.

Transl Lung Cancer Res. 2017 Apr;6(2):169-177. doi: 10.21037/tlcr.2017.03.03. Review.

16.

Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.

Lee E, Zeng J, Miyaoka RS, Saini J, Kinahan PE, Sandison GA, Wong T, Vesselle HJ, Rengan R, Bowen SR.

Med Phys. 2017 Jul;44(7):3418-3429. doi: 10.1002/mp.12308. Epub 2017 Jun 1.

17.

Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry.

Dhami G, Zeng J, Vesselle HJ, Kinahan PE, Miyaoka RS, Patel SA, Rengan R, Bowen SR.

Strahlenther Onkol. 2017 May;193(5):410-418. doi: 10.1007/s00066-017-1114-0. Epub 2017 Mar 2.

18.

Oligometastatic non-small-cell lung cancer: current treatment strategies.

Richard PJ, Rengan R.

Lung Cancer (Auckl). 2016 Nov 4;7:129-140. doi: 10.2147/LCTT.S101639. eCollection 2016. Review.

19.

First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.

Remick JS, Schonewolf C, Gabriel P, Doucette A, Levin WP, Kucharczuk JC, Singhal S, Pechet TTV, Rengan R, Simone CB 2nd, Berman AT.

Clin Lung Cancer. 2017 Jul;18(4):364-371. doi: 10.1016/j.cllc.2016.12.009. Epub 2017 Jan 5.

PMID:
28162946
20.

An image-guided precision proton radiation platform for preclinical in vivo research.

Ford E, Emery R, Huff D, Narayanan M, Schwartz J, Cao N, Meyer J, Rengan R, Zeng J, Sandison G, Laramore G, Mayr N.

Phys Med Biol. 2017 Jan 7;62(1):43-58. Epub 2016 Dec 14.

PMID:
27973343
21.

Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.

Chao HH, Berman AT, Simone CB 2nd, Ciunci C, Gabriel P, Lin H, Both S, Langer C, Lelionis K, Rengan R, Hahn SM, Prabhu K, Fagundes M, Hartsell W, Mick R, Plastaras JP.

J Thorac Oncol. 2017 Feb;12(2):281-292. doi: 10.1016/j.jtho.2016.10.018. Epub 2016 Nov 5.

22.

Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment.

Maquilan G, Grover S, Xanthopoulos E, Evans TL, Aggarwal C, Langer CJ, Cohen RB, Stevenson JP, Simone CB 2nd, Rengan R.

Am J Clin Oncol. 2018 Apr;41(4):391-395. doi: 10.1097/COC.0000000000000288.

PMID:
27100960
23.

Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB 2nd, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS; International Particle Therapy Co-operative Group Thoracic Subcommittee.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):505-16. doi: 10.1016/j.ijrobp.2016.01.036. Epub 2016 Jan 23. Review.

PMID:
27084663
24.

Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Warner A, Dahele M, Hu B, Palma DA, Senan S, Oberije C, Tsujino K, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, De Ruyck K, De Dios NR, Bradley JD, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):612-20. doi: 10.1016/j.ijrobp.2015.11.030. Epub 2015 Nov 23. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):1087.

PMID:
26867890
25.

Education and Training Needs in Radiation Oncology in India: Opportunities for Indo-US Collaborations.

Grover S, Chadha M, Rengan R, Williams TR, Morris ZS, Morgan DA, Tripuraneni P, Hu K, Viswanathan AN.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):957-60. doi: 10.1016/j.ijrobp.2015.08.009. Epub 2015 Aug 7.

PMID:
26581132
26.

Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data.

Chvetsov AV, Sandison GA, Schwartz JL, Rengan R.

Phys Med Biol. 2015 Nov 7;60(21):8491-503. doi: 10.1088/0031-9155/60/21/8491. Epub 2015 Oct 20.

PMID:
26485348
27.

Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions.

Berman AT, James SS, Rengan R.

Cancers (Basel). 2015 Jul 2;7(3):1178-90. doi: 10.3390/cancers7030831. Review.

28.

Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.

Rodrigues G, Oberije C, Senan S, Tsujino K, Wiersma T, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, DeRuyck K, De Dios NR, Warner A, Bradley JD, Palma DA.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):133-9. doi: 10.1016/j.ijrobp.2014.09.033. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1115.

PMID:
25835622
29.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

30.

Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study.

Xanthopoulos EP, Handorf E, Simone CB 2nd, Grover S, Fernandes AT, Sharma S, Corradetti MN, Evans TL, Langer CJ, Mitra N, Shah A, Apisarnthanarax S, Lin LL, Rengan R.

Pract Radiat Oncol. 2015 Jul-Aug;5(4):e355-63. doi: 10.1016/j.prro.2014.11.006. Epub 2015 Jan 31.

PMID:
25649540
31.

Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.

Kesarwala AH, Ko CJ, Ning H, Xanthopoulos E, Haglund KE, O'Meara WP, Simone CB 2nd, Rengan R.

Clin Lung Cancer. 2015 May;16(3):237-44. doi: 10.1016/j.cllc.2014.12.001. Epub 2014 Dec 9.

32.

Stereotactic body radiotherapy.

Kollar L, Rengan R.

Semin Oncol. 2014 Dec;41(6):776-89. doi: 10.1053/j.seminoncol.2014.09.022. Epub 2014 Oct 7. Review.

PMID:
25499636
33.

The use of proton therapy in the treatment of lung cancers.

Simone CB 2nd, Rengan R.

Cancer J. 2014 Nov-Dec;20(6):427-32. doi: 10.1097/PPO.0000000000000080. Review.

PMID:
25415690
34.

Dynamic simulation of motion effects in IMAT lung SBRT.

Zou W, Yin L, Shen J, Corradetti MN, Kirk M, Munbodh R, Fang P, Jabbour SK, Simone CB 2nd, Yue NJ, Rengan R, Teo BK.

Radiat Oncol. 2014 Nov 1;9:225. doi: 10.1186/s13014-014-0225-3.

35.

Combination of stereotactic ablative body radiation with targeted therapies.

Zeng J, Baik C, Bhatia S, Mayr N, Rengan R.

Lancet Oncol. 2014 Sep;15(10):e426-34. doi: 10.1016/S1470-2045(14)70026-9. Review.

PMID:
25186046
36.

Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate.

Lin LL, Mick R, Ware J, Metz J, Lustig R, Vapiwala N, Rengan R, Kennedy AR.

Oncol Lett. 2014 Apr;7(4):1151-1158. Epub 2014 Feb 5.

37.

International outreach: what is the responsibility of ASTRO and the major international radiation oncology societies?

Mayr NA, Hu KS, Liao Z, Viswanathan AN, Wall TJ, Amendola BE, Calaguas MJ, Palta JR, Yue NJ, Rengan R, Williams TR.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):481-4. doi: 10.1016/j.ijrobp.2013.12.052.

PMID:
24929158
38.

Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology survey.

Rengan R, Ho A, Owen JB, Komaki R, Khalid N, Wilson JF, Movsas B.

Pract Radiat Oncol. 2014 May-Jun;4(3):e167-e179. doi: 10.1016/j.prro.2013.07.012. Epub 2013 Oct 8.

PMID:
24766691
39.

A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Corradetti MN, Mitra N, Bonner Millar LP, Byun J, Wan F, Apisarnthanarax S, Christodouleas J, Anderson N, Simone CB 2nd, Teo BK, Rengan R.

Pract Radiat Oncol. 2013 Oct-Dec;3(4):307-15. doi: 10.1016/j.prro.2012.10.005. Epub 2012 Nov 29.

PMID:
24674403
40.

Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation.

Berman AT, Turowski J, Mick R, Cengel K, Farnese N, Basel-Brown L, Mesaros C, Blair I, Lawson J, Christofidou-Solomidou M, Lee J, Rengan R.

J Pulm Respir Med. 2013 Aug 30;3(4):154.

41.

Radiation injury to the normal brain measured by 3D-echo-planar spectroscopic imaging and diffusion tensor imaging: initial experience.

Chawla S, Wang S, Kim S, Sheriff S, Lee P, Rengan R, Lin A, Melhem E, Maudsley A, Poptani H.

J Neuroimaging. 2015 Jan-Feb;25(1):97-104. doi: 10.1111/jon.12070. Epub 2013 Nov 26.

PMID:
24279509
42.

Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.

Geiger GA, Kim MB, Xanthopoulos EP, Pryma DA, Grover S, Plastaras JP, Langer CJ, Simone CB 2nd, Rengan R.

Clin Lung Cancer. 2014 Jan;15(1):79-85. doi: 10.1016/j.cllc.2013.08.004. Epub 2013 Oct 8.

PMID:
24238934
43.

Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, Barriger RB, Moreno-Jiménez M, Kim TH, Ramella S, Everitt S, Rengan R, Marks LB, De Ruyck K, Warner A, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):690-6. doi: 10.1016/j.ijrobp.2013.07.029. Epub 2013 Sep 10. Review.

PMID:
24035329
44.

High body mass index is associated with worse quality of life in breast cancer patients receiving radiotherapy.

Fang P, Tan KS, Troxel AB, Rengan R, Freedman G, Lin LL.

Breast Cancer Res Treat. 2013 Aug;141(1):125-33. doi: 10.1007/s10549-013-2663-2. Epub 2013 Aug 14.

PMID:
23942874
45.

An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer.

Berman AT, Teo BK, Dolney D, Swisher-McClure S, Shahnazi K, Both S, Rengan R.

Radiat Oncol. 2013 Jun 15;8:144. doi: 10.1186/1748-717X-8-144.

46.

Stereotactic body radiation therapy for lung cancer.

Simone CB 2nd, Wildt B, Haas AR, Pope G, Rengan R, Hahn SM.

Chest. 2013 Jun;143(6):1784-1790. doi: 10.1378/chest.12-2580. Review.

PMID:
23732589
47.

Role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer.

Kesarwala AH, Grover S, Rengan R.

Thorac Cancer. 2013 May;4(2):95-101. doi: 10.1111/j.1759-7714.2012.00174.x. Review.

PMID:
28920191
48.

Impact of PET staging in limited-stage small-cell lung cancer.

Xanthopoulos EP, Corradetti MN, Mitra N, Fernandes AT, Kim M, Grover S, Christodouleas JP, Evans TL, Stevenson JP, Langer CJ, Lee TT, Pryma DA, Lin LL, Simone CB 2nd, Apisarnthanarax S, Rengan R.

J Thorac Oncol. 2013 Jul;8(7):899-905. doi: 10.1097/JTO.0b013e31828e8996. Erratum in: J Thorac Oncol. 2013 Aug;8(8):1106.

49.

Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study.

Rengan R, Mitra N, Liao K, Armstrong K, Vachani A.

Lancet Oncol. 2012 Dec;13(12):1203-9. doi: 10.1016/S1470-2045(12)70466-7. Epub 2012 Nov 16.

50.

Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.

Trister AD, Pryma DA, Xanthopoulos E, Kucharczuk J, Sterman D, Rengan R.

Am J Clin Oncol. 2014 Apr;37(2):135-9. doi: 10.1097/COC.0b013e31826b9cd3.

PMID:
23111361

Supplemental Content

Loading ...
Support Center